Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KIORA PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2036-06-10 | Direct | 25,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 25,000 · Balance 25,000 F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 16:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001855207-26-000002 · wk-form4_1781295365.xml · derivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001372514-25-000030 · wk-form4_1743639379.xml · derivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 07:02 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | PurchaseCommon Stock | 3,000 | $3.60 | $10,800.00 |
DisclosureSEC source: 0001372514-24-000113 · wk-form4_1726052526.xml · nonDerivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Shapiro Family Irrevocable Trust Disclosed balance after: 3,000 Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 15:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 1,778 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001372514-24-000091 · wk-form4_1720034141.xml · derivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,778 Underlying: Common Stock · 1,778 shares Expires 2034-07-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 16:46 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001372514-23-000146 · wk-form4_1696365944.xml · derivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 20:14 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001372514-23-000032 · wf-form4_167823805057575.xml · derivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-03-03 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:01 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011490 · tm225348d1_4.xml · derivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:15 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001104659-21-053166 · tm2113676d1_form4.xml · derivative · entry 1 Shapiro Aron · CIK 0001855207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2031-04-19 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 19, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.